

## Description générale

Testicular germ cell tumour  Ovarian germ cell tumour  Osteosarcoma  Rhabdomyosarcoma  Ewing sarcoma.

INN	Mesna
Codes ATC	V03AF01
Type de médicament	Chemical agent
Historique des statuts LME	<p>Ajouté pour la première fois en 2009 (TRS 958) pour <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b></p> <p>Ajouté en 2015 (TRS 994) pour <b>Osteosarcoma of bone and articular cartilage of other specified sites</b></p> <p>Ajouté en 2015 (TRS 994) pour <b>Rhabdomyosarcoma primary site</b></p> <p>Ajouté en 2015 (TRS 994) pour <b>Other specified malignant neoplasms of the ovary</b></p> <p>Ajouté en 2015 (TRS 994) pour <b>Germ cell tumour of testis</b></p> <p>Ajouté en 2015 (TRS 994) pour <b>Ewing sarcoma of bone and articular cartilage of unspecified sites</b></p> <p>Retiré en 2015 (TRS 994) pour <b>Unspecified malignant neoplasms of ill-defined or unspecified sites</b></p> <p>Ajouté en 2021 (TRS 1035) pour <b>Burkitt lymphoma including Burkitt leukaemia</b></p> <p>Ajouté en 2021 (TRS 1035) pour <b>Malignant neoplasms of kidney, except renal pelvis</b></p>
Wikipédia	<a href="#">Mesna</a> 
DrugBank	<a href="#">Mesna (Coenzyme M)</a> 

## Recommandations

Section Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule

Oral > Solid > tablet: 400 mg; 600 mg

Oral > Other: 600 mg

Oral > Solid > tablet: 400 mg

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Indications

Osteosarcoma of bone and articular cartilage of other specified sites

Rhabdomyosarcoma primary site

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

